Skip to main content
Premium Trial:

Request an Annual Quote

Spiral Genetics Completes $3M Series A Round, Partners with Omicia

NEW YORK (GenomeWeb News) – Bioinformatics firm Spiral Genetics today announced the completion of its Series A financing that raised $3 million. It also announced a partnership with Omicia.

Venture capital firm DFJ led the round and funds will go toward the development of bioinformatics tools for the analyses of large-scale genomic data. Spiral will use the money to expand its bioinformatics engineering team, scale its sales and marketing efforts, and accelerate product development, it said.

The company's cloud-based platform accelerates the data processing time from days to hours, it added, resulting in the analysis time for a whole genome at 40x coverage at about three hours.

The Seattle-based firm also announced a partnership with Omicia, which develops informatics systems for interpreting human genome sequences for research and clinical applications. The deal will leverage Omicia's Opal solution, a variant analysis tool for genome research and prioritizing disease-causing variants.

Martin Reese, co-founder, president, and CEO of Emeryville, Calif.-based Omicia, said in a statement, "Our partnership with Spiral Genetics allows faster and more accurate interpretation of human genomes for clinical relevance, a critical bottleneck for adoption of genomes into clinical care and laboratory testing.

"In combination with Omicia's Opal system, our partnership will move us closer to a seamless solution from raw sequence data to clinically relevant genomic variants. Speed and user friendliness are critical for adoption of human genome sequencing," he added.

Financial and other terms of the deal were not disclosed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.